

Remdesivir for The Treatment of Covid-19, its Safety and Clinical Effectiveness: A clinical Review

Abstract:

Remdesivir (Veklury®; Gilead Sciences) is a nucleotide analogue pro-drug and antiviral medicine with broad-spectrum effectiveness against viruses from several families. After exhibiting strong antiviral activity against coronaviruses in preclinical studies, remdesivir was approved as a candidate drug for the treatment of the novel coronavirus disease 2019 (COVID-19), which was caused by the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the current global pandemic. The Remdesivir COVID-19 phase III evaluation began in early 2020, and preliminary findings are promising. For people with severe COVID-19, Taiwan temporarily approved the use of Remdesivir in late May 2020. This was quickly followed by a number of conditional permits in many countries/regions, including the USA and Canada. Remdesivir had already been granted emergency use authorization in the USA (on May 1, 2020) and special authorization for emergency use in Japan (on 7 May 2020). This article provides a summary of remdesivir's development and the significant events that led to its initial conditional approval for the treatment of COVID-19.

Introduction:

A novel coronavirus that in December 2019 in Wuhan, Hubei Province, China, caused a number of severe viral pneumonia cases eventually spread to other parts of the world and resulted in a pandemic that was lethal. The scientific community laboured assiduously to understand the biology of this unusual disease in order to find a workable solution. By attaching to the angiotensin-converting enzyme 2 (ACE2) receptor, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infects a host and enters the host's cells. The virus then shows a preference for the epithelial cells lining the airways of the nose and lungs as well as a number of other bodily tissues (Mechineni, Kassab, & Manickam, 2021; Sungnak, Huang, & Bécavin, 2020). When the condition worsens and the coagulation cascade is set off, lung endothelial cells are affected. Due to this, a unique spectrum of clinical manifestations with multiple organ involvement is produced. This condition is now

referred to as coronavirus disease, and it manifests clinically as different stages of pneumonia with or without concurrent coagulation issues (COVID-19). COVID-19 is classified as mild, moderate, severe, or critical based on clinical signs, with oxygen supplementation being one of the most significant indirect measures of severity (Wiersinga, Rhodes, Cheng, Peacock, & Prescott, 2020; World Health, 2020).

The COVID-19 disease appears to have a range of clinical symptoms, from asymptomatic to severe respiratory failure. The initial signs of an illness are most frequently fever, coughing, and nonspecific myalgia. Less frequent signs include sputum production, headaches, and diarrhea (N. Chen et al., 2020; Huang et al., 2020; Q. Li et al., 2020). In cases from China up until mid-February 2020, a preliminary case analysis found that 14% of cases had severe disease (dyspnea, respiratory frequency $> 30/\text{min}$, blood oxygen saturation 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio 100, and/or lung infiltrates $> 50\%$ within 24-48 h), and 5% of cases had the critical disease (respiratory failure, septic shock, and/or multiple organ dysfunction or failure) (Wu & McGoogan, 2020). A more extensive meta-analysis revealed that the percentage of serious disease was slightly higher (20.3%) (Rodriguez-Morales et al., 2020). The disease case fatality rate (CFR) varies by geography, population demographics, and healthcare infrastructure; for instance, it is estimated that Italy's overall CFR is 7.2%, in part because it has a higher proportion of older people than China (Onder, Rezza, & Brusaferro, 2020). According to data from around the world, the COVID-19 CFR based on confirmed cases is predicted to be 6.9%. Advanced age, sepsis, and aberrant blood coagulation patterns were all associated with an increased risk of mortality (Dong, Du, & Gardner, 2020). Acute respiratory distress syndrome typically progresses in elderly people (over 63 years old), frequently with underlying medical issues like hypertension or diabetes (Bornstein, Dalan, Hopkins, Mingrone, & Boehm, 2020; C. Wu et al., 2020; Zhou et al., 2020). A larger body-to-mass ratio (over 30) was associated with a higher disease severity and a quicker onset of acute respiratory distress syndrome in adults under 60 (Lighter et al., 2020). Other symptoms, such as coagulo-pathies and anomalies of the nervous system, have also been observed in some afflicted individuals. (Baig, Khaleeq, Ali, & Syeda, 2020; Li, Bai, & Hashikawa, 2020; Magro et al., 2020; Mao et al., 2020; Ruggeri et al., 2022; Y. Wu et al., 2020).

1. Remdesivir's initial Design and Development:

Remdesivir (GS-5734), a drug produced by Gilead Sciences, was developed in cooperation with the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). They looked for treatments for RNA-based viruses that still had the potential to become pandemics and spread throughout the world, like those that did so after the program's inception, like EBOV and the Coronaviridae family viruses that are responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (SARS). A library of roughly 1,000 small compounds centred on nucleoside analogues was established as a place to start the discovery process based on prior knowledge of effective antiviral medicines targeting RNA viruses. They made up a large portion of the library since modified nucleosides including monophosphate, ester, and phosphoramidate prodrugs are weakly cell-permeable and can subsequently have a low hit rate in cell-based screens like antiviral screenings. The nucleoside or phosphorylated nucleoside is released by the metabolism of these prodrugs, which are typically more cellular permeable (De Clercq, 2002; Mehellou, Balzarini, & McGuigan, 2009; Seley-Radtke & Yates, 2018). An extremely successful 1'-CN modified adenosine C-nucleoside hit (GS-441524) and its mono-phosphate prodrug (GS-5734, later renamed as remdesivir) was found to exist. However, it doesn't appear that the information from the initial full screen has been made public (Siegel et al., 2017). As promising leads from a group of 10-substituted 4-aza-7,9-dideazaadenosine C-nucleosides with broad antiviral activity against a panel of RNA viruses, including SARS, influenza A, dengue virus type 2, influenza B, and yellow fever virus, GS-441524 and its S-acyl-2-thioethyl monophosphate prodrug were first introduced in 2012, they were then known as GS-441524 (YFV). The primary test used was the cytoprotective effect (CPE) assay, in which a live virus is incubated with a target cell line and the antiviral activity is determined by the ability of a test agent to delay cell death as determined by a reference cell viability reagent. In a 2012 study, the drug GS-5734 demonstrated CPE action against the SARS strain Toronto 2 (IC₅₀ = 2.2 M) without harming the kidney epithelial cells utilized as the host in the CPE assay, Vero African green monkeys (Cho et al., 2012; Green, D Ott, J Isaacs, & Fang, 2008).

2. Remdesivir Structure:

Remdesivir (GS-5734), a nucleoside analogue drug, has a broad spectrum of antiviral activity and efficiently treats lethal Ebola and Nipah virus infections in nonhuman primates (Lo & Feldmann, 2019). It works as an RNA-dependent RNA polymerase (RdRp) inhibitor to stop the replication of some corona viruses in respiratory epithelial cells. A recent study found that

Remdesivir competes with its natural counterpart ATP. Once it has been added to the growing chain I position, Remdesivir cannot cause an immediate halt. Rather, it will proceed three further nucleotides to end the strand at position I + 3 (Gordon, Tchesnokov, Feng, Porter, & Götte, 2020).




Fig:1 Structure of Remdesivir (Gordon et al., 2020)

3. Pharmacokinetics/ Pharmacodynamics of Remdesivir:

Remdesivir must be delivered intravenously for quick and reliable delivery to target cells; peak plasma concentrations are attained for remdesivir after the infusion and for GS-441524 after one to one and a half hours. The maximum concentration (C_{max}) of remdesivir is increased when the infusion period is cut from 2 hours to 30 minutes, but the C_{max} of GS-441524 is barely affected. Remdesivir has a half-life of roughly one hour in plasma concentrations, but GS-441524 has a longer half-life of almost 27 hours. Remdesivir has poor hepatic stability, which prevents oral administration because doing so would likely lead to total clearance following first-pass metabolism. Remdesivir has a 12.1% free fraction in humans, which indicates moderate protein binding. The plasma protein binding of the metabolites, GS-704277 and GS-441524, is incredibly low (1% and 2%, respectively). Remdesivir and its metabolites appear to be widely distributed throughout the kidney, liver, lungs, and artery wall with only marginal penetration of the blood-brain barrier in animal studies. GS-441524 dose-proportional increases were observed in one investigation examining drug distribution into peripheral blood mononuclear cells after different single doses of remdesivir (3 to 225 mg), which is consistent with a linear pharmacokinetic model. Remdesivir undergoes substantial metabolism after intravenous injection, starting with esterases' hydrolysis of the drug, which yields the intermediate alanine metabolite GS-

704277. Following phosphoramidase activity on GS-704277, nucleoside monophosphate is created, which can travel through two different metabolic routes. The active nucleoside triphosphate GS-443902 is produced by phosphorylating the nucleoside monophosphate, while the nucleoside GS-441524 is produced by dephosphorylating it. Additionally, M27, a significant metabolite that has not yet been named, appears to be present in plasma (Green et al., 2008; Hu et al., 2021; Zhu, Zhu, Zhu, & Sun, 2020).

4. Mechanism of action of remdesivir:

Remdesivir (GS-5734) is a prodrug of a C-adenosine nucleoside analogue that inhibits the replication of the SARS-CoV-2 virus by targeting the RNA-dependent RNA polymerase (RdRp). The purpose of remdesivir as a prodrug is to encourage improved cell wall permeability. Nucleoside triphosphate GS-441524, the pharmacologically active version of remdesivir, is produced by significant metabolism after being present intracellularly. SARS-CoV-2 RdRp competes with natural adenosine triphosphate as it inserts itself into the RNA chain using GS-441524, delaying chain termination and viral replication (Deval, 2009; Snell, 2001; Witkowski, Robins, Sidwell, & Simon, 1972).




Fig:2 Structure and mechanism of action (Frediansyah, Nainu, Dhama, Mudatsir, & Harapan, 2021)

5. Effectiveness of remdesivir in Covid-19; clinical evidence:

On October 22, 2020, the FDA approved Veklury (remdesivir) as the initial antiviral medication for COVID-19. Gilead Sciences developed the antiviral drug Remdesivir (GS-5734) as the result of significant research that started in 2009 and was first concentrated on the hepatitis C virus and respiratory syncytial virus. However, the antiviral profiling that started in 2013 and 2014 suggests that Remdesivir may have a broad-spectrum effect against a number of viruses. Gilead Sciences conducted research on Remdesivir's effectiveness against Ebola, SARS, and MERS infections in collaboration with federal agencies and university institutions. Remdesivir, a novel investigational drug, just passed SARS-CoV-2 testing (Warren *et al.*, 2016). The prodrug remdesivir (GS-5734), an adenosine nucleotide

analog, is converted to nucleoside monophosphate and phosphorylated to produce the nucleoside triphosphate derivative (Eastman et al., 2020). The essential enzyme for viral replication, viral RNA-dependent RNA-polymerase (RdRp), competes with native ATP to utilise the nucleoside triphosphate derivative, resulting in the premature termination of the viral RNA strand (Al-Tannak, Novotny, & Alhunayan, 2020; Calvin J Gordon et al., 2020). Additionally, the integrated nucleoside triphosphate form is not recognised by viral exoribonuclease-mediated proofreading (Agostini et al., 2018). According to molecular docking research, Remdesivir would bind to SARS-CoV-2 RdRp with a strong affinity, indicating its molecular mode of action (Elfiky, 2020).

Remdesivir was given by Gilead Sciences to 61 patients with severe COVID-19 disease whose oxygen saturation was below 94% on a compassionate basis. About 68% of these patients demonstrated clinical improvement. Therefore, assessing remdesivir's efficacy in the management of COVID-19 was of utmost significance. Remdesivir was administered therapeutically in all clinical studies at doses of 200 mg intravenously on day 1 and 100 mg every day after that. The effectiveness of remdesivir was assessed in the first randomized, double-blinded, placebo-controlled clinical trial in patients with severe COVID-19 who had pneumonia and oxygen saturation below 94%. For 10 days, patients were given remdesivir (n = 158) or a placebo (n = 79). Due to local efforts to contain the outbreak in Wuhan, China, this study did not reach its intended recruitment goal and was not statistically powered. Remdesivir had no impact on the length of oxygen therapy, length of hospital stay, viral load, mortality rate, or time until clinical improvement. However, remdesivir patients required less time for mechanical ventilation than those who got a placebo, even though this difference was not statistically significant. The study was stopped more frequently by individuals in the remdesivir arm due to significant side events such as respiratory failure and ARDS. Although patients receiving remdesivir had clinical improvement more quickly than those receiving a placebo, this difference was still not statistically significant. Therefore, additional clinical research is required before drawing strong conclusions (Jonathan Grein et al., 2020; Wang *et al.*, 2020).

Remdesivir is now being tested in 45 registered clinical trials for COVID-19 patients that are in the recruitment stage. Due to a lack of supporting data, the WHO issued a conditional recommendation on the use of remdesivir in hospitalized patients on November 20, 2020 (Pan et al., 2022).

6. Efficacy and safety of remdesivir:

Remdesivir was generally well tolerated, and 119 adverse events were observed, the most frequent of which were nausea and vomiting (45.40% of patients), followed by elevated liver enzymes (14.28%). At the time of data collection, 8.4% of patients had been treated or made improvements, 6.77% had passed away, and 9.16% had not. According to subgroup studies, patients under 60 years old had a considerably lower mortality rate than patients over 60 years old. Patients undergoing oxygen therapy had a considerably greater cure/improvement rate when given standard low-flow oxygen as opposed to mechanical ventilation, non-invasive ventilation, or high-flow oxygen. Age > 60 years, heart disease, diabetes, high flow oxygen, non-invasive ventilation, and mechanical ventilation were factors linked to greater mortality. Remdesivir is well tolerated and has an acceptable safety profile, according to research by VaishaliGupte et al. The clinical outcome of cure or improvement was 84%; patients under 60 years old and using regular low-flow oxygen showed greater improvements (Gupte et al., 2022).

Conclusions:

The unique coronavirus infection, which was originally discovered in Wuhan at the end of 2019, has drawn a lot of attention. Despite the fact that the number of infectious cases has reached over 100,000 worldwide and is now regarded as a pandemic, there hasn't yet been a "specific treatment" made available. Relevant research reveal that the new coronavirus and SARS are genetically very similar, sharing 80% of their genes. The problem that emerges when newly created pharmaceuticals cannot be given to patients straight away has a workable solution: "Conventional drug in novel use". Because Remdesivir was the first treatment that the recovered patients used in the US, it has earned the nickname "specific drug."

Remdesivir has also been quickly enrolled in clinical studies in China to be used as a clinical treatment for the Corona Virus Disease that would be prevalent in 2019. (COVID-19). Our starting points were the structure, immunogenicity, and pathophysiology of coronavirus infections brought on by the novel coronavirus. We also evaluated the pharmacological outcomes of previous trials with remdesivir to assess the feasibility of investigating COVID-19. As the COVID-19 epidemic spreads across the globe, the scientific community has come together to research and evaluate novel drugs and vaccines, from government laboratories to

small biotechnology companies to large pharmaceutical companies. Repurposing or repositioning an effective small-molecule medicine is the fastest treatment strategy to limit the pandemic's progress. One of the potential medicines, remdesivir, has demonstrated corona virus effectiveness both in vitro and in vivo. Recent studies on Remdesivir's ability to help COVID-19 patients experience some treatment improvement in accordance with a compassionate use indication are encouraging (Allison, 2012; Amanat & Krammer, 2020; W. H. Chen & Strych, 2020; J. Grein et al., 2020; Hodgson, 2020; Kouznetsova et al., 2014)

References:

- Allison, M. (2012). NCATS launches drug repurposing program. *Nat Biotechnol*, 30(7), 571-572.
doi:10.1038/nbt0712-571a
- Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. *Immunity*, 52(4), 583-589.
doi:10.1016/j.immuni.2020.03.007
- Baig, A. M., Khaleeq, A., Ali, U., & Syeda, H. (2020). Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. *ACS chemical neuroscience*, 11(7), 995-998.
- Bornstein, S. R., Dalan, R., Hopkins, D., Mingrone, G., & Boehm, B. O. (2020). Endocrine and metabolic link to coronavirus infection. *Nature Reviews Endocrinology*, 16(6), 297-298.
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., . . . Wei, Y. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The lancet*, 395(10223), 507-513.
- Chen, W. H., & Strych, U. (2020). The SARS-CoV-2 Vaccine Pipeline: an Overview. 7(2), 61-64.
doi:10.1007/s40475-020-00201-6
- Cho, A., Saunders, O. L., Butler, T., Zhang, L., Xu, J., Vela, J. E., . . . Kim, C. U. (2012). Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides. *Bioorganic & Medicinal Chemistry Letters*, 22(8), 2705-2707.
- De Clercq, E. (2002). Strategies in the design of antiviral drugs. *Nature Reviews drug discovery*, 1(1), 13-25.
- Deval, J. (2009). Antimicrobial strategies. *Drugs*, 69(2), 151-166.
- Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *The Lancet infectious diseases*, 20(5), 533-534.

- Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS central Science*, *6*(5), 672-683.
- Elfiky, A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life sciences*, *253*, 117592.
- Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M., & Harapan, H. (2021). Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clin Epidemiol Glob Health*, *9*, 123-127. doi:10.1016/j.cegh.2020.07.011
- Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J Biol Chem*, *295*(15), 4773-4779. doi:10.1074/jbc.AC120.013056
- Green, N., D Ott, R., J Isaacs, R., & Fang, H. (2008). Cell-based assays to identify inhibitors of viral disease. *Expert opinion on drug discovery*, *3*(6), 671-676.
- Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., . . . Lescure, F.-X. (2020). Compassionate use of remdesivir for patients with severe Covid-19. *New England journal of medicine*, *382*(24), 2327-2336.
- Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., . . . Nicastri, E. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. *382*(24), 2327-2336. doi:10.1056/NEJMoa2007016
- Gupte, V., Hegde, R., Sawant, S., Kalathingal, K., Jadhav, S., Malabade, R., & Gogtay, J. (2022). Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. *BMC Infect Dis*, *22*(1), 1. doi:10.1186/s12879-021-07004-8
- Hodgson, J. (2020). The pandemic pipeline. *Nat Biotechnol*, *38*(5), 523-532. doi:10.1038/d41587-020-00005-z
- Hu, W.-j., Chang, L., Yang, Y., Wang, X., Xie, Y.-c., Shen, J.-s., . . . Liu, J. (2021). Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. *Acta Pharmacologica Sinica*, *42*(7), 1195-1200. doi:10.1038/s41401-020-00537-9
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., . . . Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*, *395*(10223), 497-506.
- Kouznetsova, J., Sun, W., Martínez-Romero, C., Tawa, G., Shinn, P., Chen, C. Z., . . . García-Sastre, A. (2014). Identification of 53 compounds that block Ebola virus-like particle entry via a

- repurposing screen of approved drugs. *Emerg Microbes Infect*, 3(12), e84.
doi:10.1038/emi.2014.88
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., . . . Wong, J. Y. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. *New England journal of medicine*.
- Li, Y. C., Bai, W. Z., & Hashikawa, T. (2020). Response to Commentary on “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients”.
Journal of Medical Virology, 92(7), 707-709.
- Lighter, J., Phillips, M., Hochman, S., Sterling, S., Johnson, D., Francois, F., & Stachel, A. (2020). Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission.
Clinical Infectious Diseases, 71(15), 896-897.
- Lo, M. K., & Feldmann, F. (2019). Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. 11(494). doi:10.1126/scitranslmed.aau9242
- Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., . . . Laurence, J. (2020). Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Translational Research*, 220, 1-13.
- Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., . . . Jin, H. (2020). Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *MedRxiv*.
- Mechineni, A., Kassab, H., & Manickam, R. (2021). Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. *Expert Opinion on Drug Safety*, 20(11), 1299-1307. doi:10.1080/14740338.2021.1962284
- Mehellou, Y., Balzarini, J., & McGuigan, C. (2009). Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. *ChemMedChem: Chemistry Enabling Drug Discovery*, 4(11), 1779-1791.
- Onder, G., Rezza, G., & Brusaferro, S. (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *Jama*, 323(18), 1775-1776.
- Pan, H., Peto, R., Henao-Restrepo, A.-M., Preziosi, M.-P., Sathiyamoorthy, V., Abdool Karim, Q., . . . Malekzadeh, R. (2022). Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. *Lancet*, 399, 1941-1953.
- Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., . . . Henao-Martinez, A. F. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel medicine and infectious disease*, 34, 101623.

- Ruggeri, M., Signorini, A., Caravaggio, S., Alraddadi, B., Alali, A., Jarrett, J., . . . Al Musawi, T. (2022). Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study. *Clin Drug Investig*, 42(8), 669-678. doi:10.1007/s40261-022-01177-z
- Seley-Radtke, K. L., & Yates, M. K. (2018). The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. *Antiviral research*, 154, 66-86.
- Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., . . . Ross, B. (2017). Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo [2, 1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses: ACS Publications.
- Snell, N. J. (2001). Ribavirin-current status of a broad spectrum antiviral agent. *Expert opinion on pharmacotherapy*, 2(8), 1317-1324.
- Sungnak, W., Huang, N., & Bécavin, C. (2020). SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *26(5)*, 681-687. doi:10.1038/s41591-020-0868-6
- Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., . . . Lu, Q. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The lancet*, 395(10236), 1569-1578.
- Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., . . . Hui, H. C. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature*, 531(7594), 381-385.
- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *Jama*, 324(8), 782-793. doi:10.1001/jama.2020.12839
- Witkowski, J., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972). Design, synthesis, and broad spectrum antiviral activity of 1-. beta.-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides. *Journal of medicinal chemistry*, 15(11), 1150-1154.
- World Health, O. (2020). *Clinical management of COVID-19: interim guidance, 27 May 2020*. Retrieved from Geneva: <https://apps.who.int/iris/handle/10665/332196>
- Wu, C., Chen, X., Cai, Y., Zhou, X., Xu, S., Huang, H., . . . Zhang, Y. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA internal medicine*, 180(7), 934-943.

Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., . . . Yang, C. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain, behavior, and immunity*, 87, 18-22.

Wu, Z., & McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama*, 323(13), 1239-1242.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Gu, X. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*, 395(10229), 1054-1062.

Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. *Current Research in Microbial Sciences*, 1. doi:10.1016/j.crmicr.2020.06.003

UNDER PEER REVIEW